

Ben Cannon Serves as Judge and Speaker at New England Med Tech Summit

December 14, 2023

With nearly 200 innovators and 120 leading investors at the New England Summit in Boston, Massachusetts, CUE Growth was honored not only to participate but have Ben Cannon judge the Top 30 med device and med tech innovators, while serving as the summary speaker at the end of the conference on what top investment firms prioritize when evaluating an opportunity and where recent investment activity has been successfully completed.

Though there were many innovators and fields presented within med device and med tech, there were several interesting innovators within CUE Growth's heavily prioritized focus areas across cardiovascular, bioregenerative orthopedics, and microsurgical robotics. Not only are these focus areas important to CUE Growth from a mid- to late-stage round perspective, as a bridge to a likely strategic exit, but these innovators are equally important on the private equity side to either reinvigorate cash flow med tech companies thru innovation or grow value-added services companies who rely on innovators to achieve their growth objectives.

"It's always an honor to see hundreds of people in packed conference rooms lined-up to see your Co-Founder, who is a leader in med device and med tech," said Alyssa Murstein who Co-Founded the investment firm with Ben Cannon. "It is such a competitive advantage because it fuels both of our asset classes in a complementary way that gets highlighted time and again by CEOs of either innovative med device or the value-added services companies that support them."

About CUE Growth Partners

CUE Growth is a healthcare investment firm with two complementary asset classes, late-stage Venture Capital and Lower Middle Market Private Equity, to invest in specific areas of healthcare innovation and related value-added services. Our focus areas include med device & related services and provider software & tech-enabled physician services. We pursue opportunities to deploy \$10-30 million of equity per late-stage VC investment as a bridge to a strategic-sale, and up to \$100 million of equity per PE investment often with strategic-sale optionality.